Cargando…
A cross-sectional survey on the early impact of COVID-19 on the uptake of decentralised trial methods in the conduct of clinical trials
BACKGROUND: The COVID-19 pandemic significantly impacted the conduct of clinical trials through delay, interruption or cancellation. Decentralised methods in clinical trials could help to continue trials during a pandemic. This paper presents the results of an exploratory study conducted early in th...
Autores principales: | Suman, Arnela, van Es, Jasmijn, Gardarsdottir, Helga, Grobbee, Diederick E., Hawkins, Kimberly, Heath, Megan A., Mackenzie, Isla S., van Thiel, Ghislaine, Zuidgeest, Mira G. P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9535935/ https://www.ncbi.nlm.nih.gov/pubmed/36203202 http://dx.doi.org/10.1186/s13063-022-06706-x |
Ejemplares similares
-
Which decentralised trial activities are reported in clinical trial protocols of drug trials initiated in 2019–2020? A cross-sectional study in ClinicalTrials.gov
por: de Jong, Amos J, et al.
Publicado: (2022) -
Stakeholders’ views on the ethical challenges of pragmatic trials investigating pharmaceutical drugs
por: Kalkman, Shona, et al.
Publicado: (2016) -
A systematic review of methods used to conduct decentralised clinical trials
por: Rogers, Amy, et al.
Publicado: (2022) -
COVID‐19 and the Emerging Regulatory Guidance for Ongoing Clinical Trials in the European Union
por: de Jong, Amos Jochanan, et al.
Publicado: (2021) -
Opportunities and Challenges for Decentralized Clinical Trials: European Regulators’ Perspective
por: de Jong, Amos J., et al.
Publicado: (2022)